Find Ivacaftor/Tezacaftor manufacturers, exporters & distributors on PharmaCompass

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Virtual Booth

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 35 NEWS #PharmaBuzz

media
1 DATA COMPILATION #PharmaFlow
35 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions

globalSalesInformation
1 US Medicaid Prescriptions

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

13,211,860

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Ivacaftor regimen with tezacaftor, 1969264-35-4, Ivacaftor / tezacaftor, Tezacaftor / ivacaftor, Tezacaftor and ivacaftor, Ivacaftor and tezacaftor

Molecular Formula

C₅₀H₅₅F₃N₄O₉

Molecular Weight

913.0 g/mol

InChI Key

NETGOEWJJZQLCO-PKLMIRHRSA-N

1 2D Structure

Ivacaftor/Tezacaftor

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide;1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide

2.1.2 InChI

InChI=1S/C26H27F3N2O6.C24H28N2O3/c1-24(2,13-33)22-8-14-7-18(17(27)10-19(14)31(22)11-16(34)12-32)30-23(35)25(5-6-25)15-3-4-20-21(9-15)37-26(28,29)36-20;1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h3-4,7-10,16,32-34H,5-6,11-13H2,1-2H3,(H,30,35);7-13,27H,1-6H3,(H,25,28)(H,26,29)/t16-;/m1./s1

2.1.3 InChI Key

NETGOEWJJZQLCO-PKLMIRHRSA-N

2.1.4 Canonical SMILES

CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C.CC(C)(CO)C1=CC2=CC(=C(C=C2N1CC(CO)O)F)NC(=O)C3(CC3)C4=CC5=C(C=C4)OC(O5)(F)F

2.1.5 Isomeric SMILES

CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C.CC(C)(CO)C1=CC2=CC(=C(C=C2N1C[C@H](CO)O)F)NC(=O)C3(CC3)C4=CC5=C(C=C4)OC(O5)(F)F

2.2 Synonyms

2.2.1 MeSH Synonyms

1. Symdeko

2. Tezacaftor - Ivacaftor

3. Tezacaftor And Ivacaftor

4. Tezacaftor, Ivacaftor Drug Combination

5. Tezacaftor; Ivacaftor

2.2.2 Depositor-Supplied Synonyms

1. Ivacaftor Regimen With Tezacaftor

2. 1969264-35-4

3. Ivacaftor / Tezacaftor

4. Tezacaftor / Ivacaftor

5. Tezacaftor And Ivacaftor

6. Ivacaftor And Tezacaftor

7. Tezacaftor Mixture With Ivacaftor

8. Dtxsid401027914

9. 3-quinolinecarboxamide, N-(2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro-4-oxo-, Mixture With 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-(1-((2r)-2,3-dihydroxypropyl)-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1h-indol-5-yl)cyclopropanecarboxamide

2.3 Create Date

2014-02-10

3 Chemical and Physical Properties

Molecular Formula	C₅₀H₅₅F₃N₄O₉
Molecular Weight	913.0 g/mol
Hydrogen Bond Donor Count	7
Hydrogen Bond Acceptor Count	13
Rotatable Bond Count	12
Exact Mass	912.39211383 g/mol
Monoisotopic Mass	912.39211383 g/mol
Topological Polar Surface Area	192 Å²
Heavy Atom Count	66
Formal Charge	0
Complexity	1530
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Drug and Medication Information

4.1 Drug Indication

Symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (CF) aged 6 years and older who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3AG, S945L, S977F, R1070W, D1152H, 2789+5GA, 3272 26AG, and 3849+10kbCT.

5 Pharmacology and Biochemistry

5.1 ATC Code

R07AX31

R - Respiratory system

R07 - Other respiratory system products

R07A - Other respiratory system products

R07AX - Other respiratory system products

R07AX31 - Ivacaftor and tezacaftor

Digital Content

Create Content with PharmaCompass, ask us